Bildkälla: Stockfoto

Asarina Pharma: Publication of PMDD Phase IIb study - Redeye

The scientific journal Psychoneuroendocrinology recently published data of Asarina Pharma’s phase IIb study in Sepranolone for PMDD (Premenstrual dysphoric disorder), showcasing ‘significant treatment effect’.

The scientific journal Psychoneuroendocrinology recently published data of Asarina Pharma’s phase IIb study in Sepranolone for PMDD (Premenstrual dysphoric disorder), showcasing ‘significant treatment effect’.
Börsvärldens nyhetsbrev
ANNONSER